🧬 Weekly Immunology Breakthroughs: New Drug Approvals, Game-Changing Trials & Strategic Biotech Moves
🔥 Stay informed with the most important updates in Immunology, from groundbreaking clinical results to regulatory milestones and biotech innovations driving the future of autoimmune and inflammatory care.
🗞️ This week’s headlines:
💊 Rilzabrutinib Earns Orphan Drug Status for wAIHA and IgG4-RD
🧠 UPLIZNA Becomes First FDA-Approved Therapy for IgG4-Related Disease
🌿 Desentum’s Birch Pollen Vaccine Shows Long-Lasting Immune Response in Phase 1
👶 Ustekinumab Gains EC Approval for Paediatric Crohn’s Disease
🔬 Palleon’s E-602 Cleared for Phase 2 Trials in Lupus Nephritis
⚠️ Obesity Identified as Key Driver of Biologic Resistance in Psoriasis
🚺 Women Show Lower Drug Survival on Psoriasis Biologics
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on autoimmune and inflammatory diseases
#Immunology #AutoimmuneDiseases #OrphanDrugs #Pediatrics #BiotechNews #ClinicalTrials #LucidQuest #HealthcareInnovation #Psoriasis #CrohnsDisease #IgG4RD #AllergyVaccine #GlycoImmunology